Relationship Between Serum Fetuin-a Levels and Development of Diabetic Foot

Presentation Number: SAT 621
Date of Presentation: April 1st, 2017

Ahmed mohamed bahaa Eldin III*1, Nermin Sheriba II2, Yara Muhammed Eid3 and Mohamed abdelmoneim Elmikawy4
1Ain Shams University, Cairo, EGYPT, 2ain shams university, cairo, 3ain shmas university, Cairo, EGYPT, 4ain shams university

Abstract

  • Introduction: Diabetic foot is one of the major complications of diabetes and is the main reason for nontraumatic major amputations. common clinical features of diabetic foot include ulcers, foot deformity, infection, neuropathy, PAD, osteomyelitis, and gangrene. Serum fetuin‑A is a multifunctional glycoprotein, which is exclusively secreted from hepatocytes in humans. An association between insulin resistance and type 2 diabetes in individuals with high serum fetuin-A levels was reported. The role of fetuin‑A and its involvement in patients with type 2 diabetes and PAD, who commonly suffer from advanced/systemic atherosclerosis, seems to be very complex and has not been fully understood as yet.
  • Objectives: The aim of this study is to investigate the possible relationship between serum fetuin‑A levels and the development of diabetic foot.
  • Patients and Methods: The present study was conducted on 30 type 2 diabetic patients with diabetic foot, 30 type 2 diabetic patients without diabetic foot and 30 health subjects as a control. Patients were recruited from the diabetic foot clinic and Diabetes outpatient clinic at Ain-Shams University hospitals, after having a written informed consent. Laboratory assessment done included those for diabetes control using glycosylated hemoglobin (HbA1c %) by Immulant diagnostic, fasting blood sugar (FBG) and post prandial blood sugar (PPBG), Serum fetuin-A level measured by ELISA technique (Human Fetuin A (FETU-A) ELISA Kit, Sun Long Biotech Co., LTD) and diabetic foot screening and risk stratification for diabetic patients
  • Results: serum fetuin-A level was significantly higher in patients with diabetic foot (2.43 ± 0.88 g/l) in comparison to diabetic patients without diabetic foot (1.26± 0.43 g/l) with p value < 0.001 and both groups has a significantly higher fetuin-A levels than healthy controls. Both fetuin A (odds ratio 6.71 , 95% CI for OR 2.37 to 19.00 ;and p-value 0.0003 ) and duration of diabetes (odds ratio 1.24 , 95% CI for OR 1.03 to 1.48 ;and p-value 0.020 ) were independent predictors for the occurrence of diabetic foot.
  • Conclusions: The role of fetuin‑A and its involvement in patients with type 2 diabetes and PAD, who commonly suffer from advanced/systemic atherosclerosis, seems to be very complex and has not been fully understood yet.

 

Nothing to Disclose: AMB III, NS II, YME, MAE